Production & Manufacturing

Clinigen buys global rights of Imukin from Horizon Pharma

Published 27 July 2018

Clinigen Group has acquired the global rights to Imukin, a recombinant human interferon gamma-1b, from Horizon Pharma.

Horizon will retain the rights to Actimmune (recombinant human interferon gamma-1b) in the US, Canada and Japan.

Imukin is licensed in 19 countries globally to reduce the frequency of serious infections in patients with Chronic Granulomatous Disease (CGD) and for the treatment of Severe Malignant Osteopetrosis (SMO), both considered rare conditions.

Clinigen will revitalise Imukin by working with healthcare professionals to ensure its benefits to patients are well understood. The Group will also make the medicine available to those who need it through the Group’s global distribution network for both licensed and unlicensed supply.

Imukin is the second global acquisition of a biologic by Clinigen following the acquisition of the global rights (outside the US) of Proleukin from Novartis on 17 July 2018.

Clinigen group CEO Shaun Chilton said: “Imukin strengthens our commercial offering and represents a good strategic fit with our medicines portfolio growth strategy focused on products in oncology and rare diseases.”

Clinigen chief business officer David Bryant said:“Our second acquisition in recent weeks delivers on our long term strategy of acquiring global rights to assets with the aim of revitalising and returning them back to the broadest possible access.”

Source: Company Press Release